Alana Hippensteele, Editor

The FDA has approved the monoclonal antibody mepolizumab as a treatment for patients with chronic rhinosinusitis with nasal polyps.

Workflow in the clinic and the pharmacy are critical for the implementation of a new and novel medication therapy, such as cabotegravir-rilpivirine.

Zoster vaccine recombinant, adjuvanted has been approved by the FDA for the prevention of herpes zoster in adults 18 years of age and older who are, or will be, at an increased risk of shingles because of immunodeficiency or immunosuppression.

Trials assessing psychedelic medicine were conducted in the United States for several decades before they were criminalized in 1968, with government and military funding provided for research in the field.

The FDA has approved pembrolizumab in combination with lenvatinib for the treatment of advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient

The FDA has approved the first and only intravenous immunoglobulin indicated for use in adults with dermatomyositis.

The FDA has approved finerenone for the treatment of adult patients with chronic kidney disease associated with type 2 diabetes.

The FDA has granted enfortumab vedotin-ejfv both a regular approval and a new indication expansion for the treatment of adult patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin-containing chemotherapy and have previously received 1 or more prior lines of therapy.

Ribociclib was found to prolong overall survival and improve post-progression outcomes in patients with HR-positive/HER2−negative advanced breast cancer, particularly among younger patients with a significant unmet need.

A study comparing once-monthly injectable galcanezumab-gnlm with rimegepant has been planned to support the assessment of potential treatments to prevent migraines.

Primary results from the randomized portion of the INVICTUS study had previously shown that ripretinib was able to significantly improve progression-free survival with a clinically meaningful overall survival benefit in patients with advanced gastrointestinal stromal tumor.

From Tuesday, June 22 to Saturday, June 26, customers getting a COVID-19 vaccination at Walgreens pharmacies will receive $25 in Walgreens cash rewards for in-store purchases.

Positive topline results have been published from a phase 3 trial assessing the CD-19 directed CAR T cell therapy lisocabtagene maraleucel as a second-line treatment in adults with relapsed or refractory LBCL.

Phase 2 clinical trial results assessing sotorasib in previously treated patients with NSCLC showed that the drug presented a median OS of 12.5 months among 124 patients.

Home infusion within the larger ambulatory infusion setting poses specific advantages and disadvantages in relation to other available location options.

Results from part A of a phase 3 trial showed sutimlimab caused patients to experience a rapid and sustained inhibition of C1-activated hemolysis in patients with cold agglutinin disease.

Researchers observed the structure of a lethal toxin produced by certain strains of Clostridium difficile bacteria.

The Novavax COVID-19 vaccine NVX-CoV2373 demonstrated 100% protection against moderate and severe disease and 90.4% efficacy overall in a phase 3 trial.

Data from a phase 3 trial comparing acalabrutinib against ibrutinib in adults with previously treated CLL showed acalabrutinib presented with non-inferior PFS and significantly fewer events of atrial fibrillation.

Phase 3 data presented at the 2021 ASCO Annual Meeting have reinforced the long-term survival benefits and well-established safety profile of single-agent ibrutinib for patients with CLL.

The definition of oligometastatic disease has continued to be shrouded in uncertainty due to the varying assessment criteria that exist at present during trial analyses.

The medieval era was a horrible time to be alive, with all manner of unpleasant and disfiguring diseases raging the public with no known cures, leaving the hands of a king as their last hope for salvation.

Frequent prostate-specific antigen screenings may lower the risk of metastasis at the time of diagnosis and lower mortality risk from prostate cancer among younger African American men.

Launched in 2020, a diabetes pilot program resulted in a significant improvement in patient outcomes for those enrolled.

In the 18th century, Franz Friedrich Anton Mesmer introduced the healing power of animal magnetism to Europe.

Final data from a phase 3 trial assessing evolocumab in patients with HIV who have high cholesterol confirmed the safety and efficacy of the drug as a treatment.

When a patient recovering from gonorrhea was fed the powder of the kuchila molung plant, the patient quickly suffered from much more than painful urination.

Data from the phase 3 VOYAGER PAD study demonstrated that rivaroxaban at 2.5 mg twice daily in combination with aspirin at 100 mg once daily was able to reduce severe vascular events in patients with PAD.

Patient engagement programs should continually evolve in order to meet patient needs and behaviors.

The implementation of multi-gene panel testing may be a necessary part of the standard of care for all colorectal cancer patients.